Towards isozyme-selective HDAC inhibitors for interrogating disease

Current Topics in Medicinal Chemistry

Volumn 12, Issue 14, 2012, Pages 1479-1499

  Gupta, Praveer ^a   Reid, Robert C ^a   Iyer, Abishek ^a   Sweet, Matthew J ^a   Fairlie, David P ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cancer; HDAC inhibitor; Histone deacetylase; Inflammation; Isoform; Isozyme; Metabolic

Indexed keywords

APICIDIN; AZUMAMIDE E; BELINOSTAT; BUTYRIC ACID; DACINOSTAT; ENTINOSTAT; FR 235222; FUNCTIONAL GROUP; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; ISOENZYME; MOCETINOSTAT; PANOBINOSTAT; RESMINOSTAT; ROMIDEPSIN; SB 939; TACEDINALINE; TRAPOXIN B; TRICHOSTATIN A; TUBACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ZINC;

ANTIINFLAMMATORY ACTIVITY; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CRYSTAL STRUCTURE; DEVELOPMENTAL BIOLOGY; DOSE RESPONSE; DRUG DESIGN; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; HEART DISEASE; HUMAN; IC 50; INFECTION; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; MOLECULAR BIOLOGY; NEUTROPENIA; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA;

DISEASE; DRUG DISCOVERY; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; ISOENZYMES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 84866930332     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612802652420     Document Type: Article

References (135)

1. Choudhary, C.; Kumar, C.; Gnad, F.; Nielsen, M.L.; Rehman, M.; Walther, T.C.; Olsen, J.V.; Mann, M., Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science, 2009, 325 (5942), 834-840.
2. Norvell, A.; McMahon, S.B.; Cell biology. Rise of the rival. Science, 2010, 327 (5968), 964-965.
3. Weinert, B.T.; Wagner, S.A.; Horn, H.; Henriksen, P.; Liu, W.R.; Olsen, J.V.; Jensen, L.J.; Choudhary, C., Proteome-wide mapping of the Drosophila acetylome demonstrates a high degree of conservation of lysine acetylation. Sci. Signal. 2011, 4 (183), ra48.
4. Shakespear, M.R.; Halili, M.A.; Irvine, K.M.; Fairlie, D.P.; Sweet, M.J. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol., 2011, 32 (7), 335-343.
5. Iyer, A.; Fairlie, D.P.; Brown, L. Lysine acetylation in obesity, diabetes and metabolic disease. Immunol. Cell Biol. 2012, 90(1), 39-46.
6. Halili, M.A.; Andrews, M.R.; Sweet, M.J.; Fairlie, D.P. Histone deacetylase inhibitors in inflammatory disease. Curr. Top. Med. Chem., 2009, 9(3), 309-319.
7. Balasubramanian, S.; Verner, E.; Buggy, J.J. Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett., 2009, 280 (2), 211-221.
8. Sweet, M.J.; Shakespear, M.R.; Kamal, N.A.; Fairlie, D.P. HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation. Immunol. Cell Biol., 2012, 90 (1), 14-22.
9. McKinsey, T.A. Targeting inflammation in heart failure with histone deacetylase inhibitors. Mol. Med., 2011, 17 (5-6), 434-441.
10. Bush, E.W.; McKinsey, T.A. Targeting histone deacetylases for heart failure. Expert Opin. Ther. Targets, 2009, 13 (7), 767-784.
11. Hancock, W.W. Rationale for HDAC inhibitor therapy in autoimmunity and transplantation. Handb. Exp. Pharmacol., 2011, 206, 103-123.
12. Haberland, M.; Montgomery, R.L.; Olson, E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 2009, 10 (1), 32-42.
13. Mihaylova, M.M.; Vasquez, D.S.; Ravnskjaer, K.; Denechaud, P.D.; Yu, R.T.; Alvarez, J.G.; Downes, M.; Evans, R.M.; Montminy, M.; Shaw, R.J. Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell, 2011, 145(4), 607-621.
14. Winkler, R.; Benz, V.; Clemenz, M.; Bloch, M.; Foryst-Ludwig, A.; Wardat, S.; Witte, N.; Trappiel, M.; Namsolleck, P.; Mai, K.; Spranger, J.; Matthias, G.; Roloff, T.; Truee, O.; Kappert, K.; Schupp, M.; Matthias, P.; Kintscher, U. Histone deacetylase 6 (HDAC6) is an essential modifier of glucocorticoid-induced hepatic gluconeogenesis. Diabetes, 2012, 61(2), 513-523.
15. Bai, G.; Wei, D.; Zou, S.; Ren, K.; Dubner, R. Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia. Molecular Pain, 2010, 6, 51.
16. de Zoeten, E.F.; Wang, L.; Sai, H.; Dillmann, W.H.; Hancock, W.W. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology, 2010, 138(2), 583-594.
17. de Zoeten, E.F.; Wang, L; Butler, K.; Beier, U.H.; Akimova, T.; Sai, H.; Bradner, J.E.; Mazitschek, R.; Kozikowski, A.P.; Matthias, P.; Hancock, W.W., Histone deacetylase 6 and heat shock protein 90 control the function of Foxp3 (+)T-regulatory cells. Mol. Cell Bio., 2011, 31 (10), 2066-2078.
18. Kim, H.J.; Rowe, M.; Ren, M.; Hong, J.S.; Chen, P.S.; Chuang, D.M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther., 2007, 321(3), 892-901.
19. Hockly, E.; Richon, V.M.; Woodman, B.; Smith, D.L.; Zhou, X.; Rosa, E.; Sathasivam, K.; Ghazi-Noori, S.; Mahal, A.; Lowden, P.A.; Steffan, J.S.; Marsh, J.L.; Thompson, L.M.; Lewis, C.M.; Marks, P.A.; Bates, G.P. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA 2003, 100(4), 2041-2046.
20. Chang, J.G.; Hsieh-Li, H.M.; Jong, Y.J.; Wang, N.M.; Tsai, C.H.; Li, H., Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl. Acad. Sci. USA 2001, 98(17), 9808-9813.
21. Outeiro, T.F.; Kontopoulos, E.; Altmann, S.M.; Kufareva, I.; Strathearn, K.E.; Amore, A.M.; Volk, C.B.; Maxwell, M.M.; Rochet, J.C.; McLean, P.J.; Young, A.B.; Abagyan, R.; Feany, M.B.; Hyman, B.T.; Kazantsev, A.G., Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science, 2007, 317(5837), 516-519.
22. Qing, H.; He, G.; Ly, P.T.; Fox, C.J.; Staufenbiel, M.; Cai, F.; Zhang, Z.; Wei, S.; Sun, X.; Chen, C.H.; Zhou, W.; Wang, K.; Song, W., Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J. Exp. Med., 2008, 205(12), 2781-2789.
23. Kim, H.J.; Bae, S.C., Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl. Res. 2011, 3(2), 166-179.
24. Montgomery, R.L.; Davis, C.A.; Potthoff, M.J.; Haberland, M.; Fielitz, J.; Qi, X.; Hill, J.A.; Richardson, J.A.; Olson, E.N., Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 2007, 21(14), 1790-1802.
25. Ma, P.; Pan, H.; Montgomery, R.L.; Olson, E.N.; Schultz, R.M., Compensatory functions of histone deacetylase 1 (HDAC1) and HDAC2 regulate transcription and apoptosis during mouse oocyte development. Proc. Natl. Acad. Sci. USA 2012, 109(8), 481-489.
26. Montgomery, R.L.; Hsieh, J.; Barbosa, A.C.; Richardson, J.A.; Olson, E., Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development. Proc. Natl. Acad. Sci. USA 2009, 106(19), 7876-7881.
27. Jawerka, M.; Colak, D.; Dimou, L.; spiller, C.; Lagger, S.; Montgomery, R.L.; Olson, E.N.; Wurst, W.; Gottlicher, M.; Gotz, M., The specific role of histone deacetylase 2 in adult neurogenesis. Neuron glia biology, 2010, 6(2), 93-107
28. Knutson, S.K.; Chyla, B.J.; Amann, J.M.; Bhaskara, S.; Huppert, S.S.; Hiebert, S.W., Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. Embo J. 2008, 27(7), 1017-1028.
29. Mullican, S.E.; Gaddis, C.A.; Alenghat, T., Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation. Genes Dev. 2011, 25, 2480-2488.
30. Montgomery, R.L.; Potthoff, M.J.; Haberland, M.; Qi, X.; Matsuzaki, S.; Humphries, K.M.; Richardson, J.A.; Bassel-Duby, R.; Olson, E.N., Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J. Clin. Invest., 2008, 118(11), 3588-3597.
31. Trivedi, C.M.; Lu, M.M.; Wang, Q.; Epstein, J.A., Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy. J. Biol. Chem., 2008, 283(39), 26484-26489.
32. Haberland, M.; Mokalled, M.H.; Montgomery, R.L.; Olson, E.N., Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes Dev. 2009, 23 (14), 1625-1630.
33. Vega, R.B.; Matsuda, K.; Oh, J.; Barbosa, A.C.; Yang, X.; Meadows, E.; McAnally, J.; Pomajzl, C.; Shelton, J.M.; Richardson, J.A.; Karsenty, G.; Olson, E.N., Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004, 119(4), 555-566.
34. Chang, S.; McKinsey, T.A.; Zhang, C.L.; Richardson, J.A.; Hill, J.A.; Olson, E.N., Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol. Cell Biol., 2004, 24(19), 8467-8476.
35. Chang, S.; Young, B.D.; Li, S.; Qi, X.; Richardson, J.A.; Olson, E.N., Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell, 2006, 126(2), 321-334.
36. Zhang, Y.; Kwon, S.; Yamaguchi, T.; Cubizolles, F.; Rousseaux, S.; Kneissel, M.; Cao, C.; Li, N.; Cheng, H.L.; Chua, K.; Lombard, D.; Mizeracki, A.; Matthias, G.; Alt, F.W.; Khochbin, S.; Matthias, P., Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol. Cell. Biol., 2008, 28(5), 1688-1701.
37. de Zoeten, E.F.; Wang, L.; Butler, K.; Beier, U.H.; Akimova, T.; Sai, H.; Bradner, J.E.; Mazitschek, R.; Kozikowski, A.P.; Matthias, P.; Hancock, W.W., Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol. Cell. Biol., 2011, 31(10), 2066-2078.
38. de Zoeten, E.F.; Wang, L.; Sai, H.; Dillmann, W.H.; Hancock, W.W., Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology, 2010, 138(2), 583-594.
39. Zhao, S.; Xu, W.; Jiang, W.; Yu, W.; Lin, Y.; Zhang, T.; Yao, J.; Zhou, L.; Zeng, Y.; Li, H.; Li, Y.; Shi, J.; An, W.; Hancock, S.M.; He, F.; Qin, L.; Chin, J.; Yang, P.; Chen, X.; Lei, Q.; Xiong, Y.; Guan, K.L., Regulation of cellular metabolism by protein lysine acetylation. Science 2010, 327, (5968), 1000-1004.
40. Mihaylova, M.M.; Vasquez, D.S.; Ravnskjaer, K.; Denechaud, P.D.; Yu, R.T.; Alvarez, J.G.; Downes, M.; Evans, R.M.; Montminy, M.; Shaw, R.J., Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell, 2011, 145(4), 607-621.
41. Winkler, R.; Benz, V.; Clemenz, M.; Bloch, M.; Foryst-Ludwig, A.; Wardat, S.; Witte, N.; Trappiel, M.; Namsolleck, P.; Mai, K.; Spranger, J.; Matthias, G.; Roloff, T.; Truee, O.; Kappert, K.; Schupp, M.; Matthias, P.; Kintscher, U., Histone deacetylase 6 (HDAC6) is an essential modifier of glucocorticoid-induced hepatic gluconeogenesis. Diabetes, 2012, 61(2), 513-523.
42. Darkin-Rattray, S.J.; Gurnett, A.M.; Myers, R.W.; Dulski, P.M.; Crumley, T.M.; Allocco, J.J.; Cannova, C.; Meinke, P.T.; Colletti, S.L.; Bednarek, M.A.; Singh, S.B.; Goetz, M.A.; Dombrowski, A.W.; Polishook, J.D.; Schmatz, D.M., Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. USA 1996, 93(23), 13143-13147.
43. Dow, G.S.; Chen, Y.; Andrews, K.T.; Caridha, D.; Gerena, L.; Gettayacamin, M.; Johnson, J.; Li, Q.; Melendez, V.; Obaldia, N., 3rd; Tran, T.N.; Kozikowski, A.P., Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors. Antimicrob. Agents Chemother., 2008, 52(10), 3467-3477.
44. Qiu, L.; Burgess, A.; Fairlie, D.P.; Leonard, H.; Parsons, P.G.; Gabrielli, B.G. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol. Biol. Cell. 2000, 11, 2069-83
45. Andrews, K.T.; Tran, T.N.; Wheatley, N.C.; Fairlie, D.P., Targeting histone deacetylase inhibitors for anti-malarial therapy. Curr. Top. Med. Chem. 2009, 9(3), 292-308.
46. Andrews, K.T.; Tran, T.N.; Lucke, A.J.; Kahnberg, P.; Le, G.T.; Boyle, G.M.; Gardiner, D.L.; Skinner-Adams, T.S.; Fairlie, D.P., Potent antimalarial activity of histone deacetylase inhibitor analogues. Antimicrob. Agents Chemother. 2008, 52(4), 1454-1461.
47. Halilli, M.A.; Andrews, M.R.; Labzin, L.I.; Schroder, K.; Matthias, G.; Cao, C.; Lovelace, E.; Reid, R.C.; Le, G.T.; Hume, D.A.; Irvine, K.M.; Matthias, P.; Fairlie, D.P.; Sweet, M.J., Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J. Leuko. Bio. 2010, 87(6), 1103-1114.
48. Leoni, F.; Zaliani, A.; Bertolini, G.; Porro, G.; Pagani, P.; Pozzi, P.; Dona, G.; Fossati, G.; Sozzani, S.; Azam, T.; Bufler, P.; Fantuzzi, G.; Goncharov, I.; Kim, S.H.; Pomerantz, B.J.; Reznikov, L.L.; Siegmund, B.; Dinarello, C.A.; Mascagni, P., The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. USA 2002, 99(5), 2995-3000.
49. Glauben, R.; Batra, A.; Fedke, I.; Zeitz, M.; Lehr, H.A.; Leoni, F.; Mascagni, P.; Fantuzzi, G.; Dinarello, C.A.; Siegmund, B., Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 2006, 176(8) 5015-5022.
50. Glauben, R.; Siegmund, B., Inhibition of histone deacetylases in inflammatory bowel diseases. Mol. Med. 2011, 17(5-6), 426-433.
51. Segain, J.P.; Raingeard de la Bletiere, D.; Bourreille, A.; Leray, V.; Gervois, N.; Rosales, C.; Ferrier, L.; Bonnet, C.; Blottiere, H.M.; Galmiche, J.P., Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut, 2000, 47(3), 397-403.
52. Faggioni, R.; Jones-Carson, J.; Reed, D.A.; Dinarello, C.A.; Feingold, K.R.; Grunfeld, C.; Fantuzzi, G., Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18. Proc. Natl. Acad. Sci. USA 2000, 97(5), 2367-2372.
53. Lee, T.M.; Lin, M.S.; Chang, N.C., Inhibition of histone deacetylase on ventricular remodeling in infarcted rats. Am. J. Physiol. Heart. Circ. Physiol. 2007, 293(2), H968-977.
54. Iyer, A.; Fenning, A.; Lim, J.; Le, G.T.; Reid, R.C.; Halili, M.A.; Fairlie, D.P.; Brown, L., Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br. J. Pharmacol. 2010, 159(7), 1408-1417.
55. Wang, H.; Yu, N.; Chen, D.; Lee, K.C.; Lye, P.L.; Chang, J.W.; Deng, W.; Ng, M.C.; Lu, T.; Khoo, M.L.; Poulsen, A.; Sangthongpitag, K.; Wu, X.; Hu, C.; Goh, K.C.; Wang, X.; Fang, L.; Goh, K.L.; Khng, H.H.; Goh, S.K.; Yeo, P.; Liu, X.; Bonday, Z.; Wood, J.M.; Dymock, B.W.; Kantharaj, E.; Sun, E.T., Discovery of (2E)-3-{2-Butyl-1-[2-(diethylamino)ethyl]-1Hbenzimidazol-5-yl}-N-hydroxyaacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile. J. Med. Chem., 2011, 54(13), 4694-4720.
56. Sumanadasa, S.D.; Goodman, C.D.; Lucke, A.J.; Skinner-Adams, T.; Sahama, I.; Haque, A.; Do, T.A.; McFadden, G.I.; Fairlie, D.P.; Andrews, K.T. Anti-malarial activity of the anti-cancer HDAC inhibitor SB939. Antimicrob. Agents Chemother., 2012, 56(7), 3849-56.
57. Duvic, M.; Vu, J., Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert. Opin. Investig. Drugs, 2007, 16(7), 1111-1120.
58. Piekarz, R.L.; Frye, R.; Prince, H.M.; Kirschbaum, M.H.; Zain, J.; Allen, S.L.; Jaffe, E.S.; Ling, A.; Turner, M.; Peer, C.J.; Figg, W.D.; Steinberg, S.M.; Smith, S.; Joske, D.; Lewis, I.; Hutchins, L.; Craig, M.; Fojo, A.T.; Wright, J.J.; Bates, S.E., Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood, 2011, 117(22), 5827-5834.
59. Sandor, V.; Bakke, S.; Robey, R.W.; Kang, M.H.; Blagosklonny, M.V.; Bender, J.; Brooks, R.; Piekarz, R.L.; Tucker, E.; Figg, W.D.; Chan, K.K.; Goldspiel, B.; Fojo, A.T.; Balcerzak, S.P.; Bates, S.E., Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res., 2002, 8(3), 718-728.
60. Traynor, A.M.; Dubey, S.; Eickhoff, J.C.; Kolesar, J.M.; Schell, K.; Huie, M.S.; Groteluschen, D.L.; Marcotte, S.M.; Hallahan, C.M.; Weeks, H.R.; Wilding, G.; Espinoza-Delgado, I.; Schiller, J.H., Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J. Thorac. Oncol., 2009, 4(4), 522-526.
61. Shah, M.H.; Binkley, P.; Chan, K.; Xiao, J.; Arbogast, D.; Collamore, M.; Farra, Y.; Young, D.; Grever, M., Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin. Cancer Res. 2006, 12(13), 3997-4003.
62. Choi, J.H.; Nam, K.H.; Kim, J.; Baek, M.W.; Park, J.E.; Park, H.Y.; Kwon, H.J.; Kwon, O.S.; Kim, D.Y.; Oh, G.T., Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptordeficient mice. Arterioscler. Thromb. Vasc. Biol., 2005, 25(11), 2404-2409.
63. Johnstone, R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug. Discov. 2002, 1(4), 287-299.
64. Acharya, M.R.; Sparreboom, A.; Venitz, J.; Figg, W.D., Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol. Pharmacol. 2005, 68(4), 917-932.
65. Guardiola, A.R.; Yao, T.P. Molecular cloning and characterization of a novel histone deacetylase HDAC10. J. Biol. Chem., 2002, 277(5), 3350-3356.
66. Gurvich, N.; Tsygankova, O.M.; Meinkoth, J.L.; Klein, P.S. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res., 2004, 64, (3), 1079-1086.
67. Finnin, M.S.; Donigian, J.R.; Cohen, A.; Richon, V.M.; Rifkind, R.A.; Marks, P.A.; Breslow, R.; Pavletich, N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 1999, 401(6749), 188-193.
68. Lombardi, P.M.; Cole, K.E.; Dowling, D.P.; Christianson, D.W. Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes. Curr. Opin. Struct. Biol., 2011, 735-743.
69. Vannini, A.; Volpari, C.; Filocamo, G.; Casavola, E.C.; Brunetti, M.; Renzoni, D.; Chakravarty, P.; Paolini, C.; De Francesco, R.; Gallinari, P.; Steinkuhler, C.; Di Marco, S., Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. USA 2004, 101(42), 15064-15069.
70. Maulucci, N.; Chini, M.G.; Micco, S.D.; Izzo, I.; Cafaro, E.; Russo, A.; Gallinari, P.; Paolini, C.; Nardi, M.C.; Casapullo, A.; Riccio, R.; Bifulco, G.; Riccardis, F.D. Molecular insights into azumamide e histone deacetylases inhibitory activity. J. Am. Chem. Soc., 2007, 129(10), 3007-3012.
71. Furumai, R.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Yoshida, M.; Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA 2001, 98(1), 87-92.
72. Jones, P.; Altamura, S.; Chakravarty, P.K.; Cecchetti, O.; De Francesco, R.; Gallinari, P.; Ingenito, R.; Meinke, P.T.; Petrocchi, A.; Rowley, M.; Scarpelli, R.; Serafini, S.; Steinkuhler, C. A series of novel, potent, and selective histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(23), 5948-5952.
73. Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K.H.; Nishiyama, M.; Nakajima, H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res., 2002, 62(17), 4916-4921.
74. Haggarty, S.J.; Koeller, K.M.; Wong, J.C.; Butcher, R.A.; Schreiber, S.L. Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. Chem. Biol. 2003, 10(5), 383-396.
75. Estiu, G.; Greenberg, E.; Harrison, C.B.; Kwiatkowski, N.P.; Mazitschek, R.; Bradner, J.E.; Wiest, O. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J. Med. Chem., 2008, 51(10), 2898-2906.
76. Kozikowski, A.P.; Tapadar, S.; Luchini, D.N.; Kim, K.H.; Billadeau, D.D. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J. Med. Chem., 2008, 51(15), 4370-4373.
77. Andrianov, V.; Gailite, V.; Lola, D.; Loza, E.; Semenikhina, V.; Kalvinsh, I.; Finn, P.; Petersen, K.D.; Ritchie, J.W.; Khan, N.; Tumber, A.; Collins, L.S.; Vadlamudi, S.M.; Bjorkling, F.; Sehested, M., Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR. Eur. J. Med. Chem., 2009, 44, (3), 1067-1085.
78. Schafer, S.; Saunders, L.; Eliseeva, E.; Velena, A.; Jung, M.; Schwienhorst, A.; Strasser, A.; Dickmanns, A.; Ficner, R.; Schlimme, S.; Sippl, W.; Verdin, E., Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). Bioorg. Med. Chem., 2008, 16(4), 2011-2033.
79. Schafer, S.; Saunders, L.; Schlimme, S.; Valkov, V.; Wagner, J.M.; Kratz, F.; Sippl, W.; Verdin, E.; Jung, M., Pyridylalaninecontaining hydroxamic acids as selective HDAC6 inhibitors. Chem. Med. Chem., 2009, 4(2), 283-290.
80. Neelarapu, R.; Holzle, D.L.; Velaparthi, S.; Bai, H.; Brunsteiner, M.; Blond, S.Y.; Petukhov, P.A., Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole-and pyrazole-based histone deacetylase probes. J. Med. Chem., 2011, 54(13), 4350-4364.
81. Mai, A.; Valente, S.; Nebbioso, A.; Simeoni, S.; Ragno, R.; Massa, S.; Brosch, G.; De Bellis, F.; Manzo, F.; Altucci, L., New pyrrolebased histone deacetylase inhibitors: binding mode, enzyme-and cell-based investigations. Int. J. Biochem. Cell. Biol., 2009, 41(1), 235-247.
82. Kahnberg, P.; Lucke, A.J.; Glenn, M.P.; Boyle, G.M.; Tyndall, J.D.; Parsons, P.G.; Fairlie, D.P., Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from alpha-aminosuberic acid. J. Med. Chem., 2006, 49(26), 7611-7622.
83. Glenn M.P.; Kahnberg, P.; Boyle, G.M.; Hansford, K.A.; Hans, D.; Martyn; A.C.; Parsons, P.G.; Fairlie, D.P. Antiproliferative and phenotype-transforming antitumor agents derived from cysteine. J. Med. Chem. 2004, 47(12), 2984-2994
84. Gupta, P.K.; Reid, R.C.; Liu, L.; Lucke, A.J.; Broomfield, S.A.; Andrews, M.R.; Sweet, M.J.; Fairlie, D.P., Inhibitors selective for HDAC6 in enzymes and cells. Bioorg. Med. Chem. Lett., 2010, 20(23), 7067-7070.
85. Andrews, K.T.; Gupta, A.P.; Tran, T.N.; Fairlie, D.P.; Gobert, G.N.; Bozdech, Z. Comparative gene expression profiling of P. falciparum malaria parasites exposed to three different histone deacetylase inhibitors. PLoS One, 2012, 7, e31847
86. Wheatley, N.C.; Andrews, K.T.; Tran, T.L.; Lucke, A.J.; Reid, R.C.; Fairlie, D.P. Anti-malarial histone deacetylase inhibitors containing cinnamate or NSAID components. Bioorg. Med. Chem. Lett., 2010, 20, 7080-4
87. Cantley, M.D.; Fairlie, D.P.; Bartold, P.M.; Rainsford, K.D.; Le, G.T.; Lucke, A.J.; Holding, C.A.; Haynes, D.R. Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro. J. Cell Physiol., 2011, 226, 3233-3241
88. Cantley, M.D.; Bartold, P.M.; Mariano, V.; Fairlie, D.P.; Le, G.T.; Lucke, A.J.; Haynes, D.R. Histone deacetylase inhibitors and periodontal bone loss. J. Periodontal Res., 2011, 46, 697-703.
89. Marfurt, J.; Chalfein, F.; Prayoga, P.; Wabiser, F.; Kenangalem, E.; Piera, K. A.; Fairlie, D. P.; Tjitra, E.; Anstey, N. M.; Andrews, K. T.; Price, R. N. Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax. Antimicrobial Antiinfectives Chemother. 2011, 55, 961-966.
90. Shinji, C.; Maeda, S.; Imai, K.; Yoshida, M.; Hashimoto, Y.; Miyachi, H., Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem., 2006, 14(22), 7625-7651.
91. Smil, D.V.; Manku, S.; Chantigny, Y.A.; Leit, S.; Wahhab, A.; Yan, T.P.; Fournel, M.; Maroun, C.; Li, Z.; Lemieux, A.M.; Nicolescu, A.; Rahil, J.; Lefebvre, S.; Panetta, A.; Besterman, J.M.; Deziel, R., Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, (3), 688-692.
92. Giannini, G.; Marzi, M.; Marzo, M.D.; Battistuzzi, G.; Pezzi, R.; Brunetti, T.; Cabri, W.; Vesci, L.; Pisano, C., Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(10), 2840-2843.
93. Butler, K.V.; Kalin, J.; Brochier, C.; Vistoli, G.; Langley, B.; Kozikowski, A.P. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J. Am. Chem. Soc., 2010, 132(31), 10842-10846.
94. Shen, J.; Woodward, R.; Kedenburg, J.P.; Liu, X.; Chen, M.; Fang, L.; Sun, D.; Wang, P.G., Histone deacetylase inhibitors through click chemistry. J. Med. Chem. 2008, 51(23), 7417-7427.
95. Tapadar, S.; He, R.; Luchini, D.N.; Billadeau, D.D.; Kozikowski, A.P. Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg. Med. Chem. Lett., 2009, 19(11), 3023-3026.
96. Zhang, Y.; Fang, H.; Feng, J.; Jia, Y.; Wang, X.; Xu, W., Discovery of a Tetrahydroisoquinoline-Based Hydroxamic Acid Derivative (ZYJ-34c) as Histone Deacetylase Inhibitor with Potent Oral Antitumor Activities. J. Med. Chem., 2011, 54(15), 5532-5539.
97. Park, J.H.; Jung, Y.; Kim, T.Y.; Kim, S.G.; Jong, H.S.; Lee, J.W.; Kim, D.K.; Lee, J.S.; Kim, N.K.; Bang, Y.J. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin. Cancer Res., 2004, 10, (15), 5271-5281.
98. Krennhrubec, K.; Marshall, B.L.; Hedglin, M.; Verdin, E.; Ulrich, S.M., Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg. Med. Chem. Lett. 2007, 17(10), 2874-2878.
99. Tessier, P.; Smil, D.V.; Wahhab, A.; Leit, S.; Rahil, J.; Li, Z.; Deziel, R.; Besterman, J.M., Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(19), 5684-5688.
100. Choi, E.; Lee, C.; Park, J.E.; Seo, J.J.; Cho, M.; Kang, J.S.; Kim, H.M.; Park, S.K.; Lee, K.; Han, G. Structure and property based design, synthesis and biological evaluation of gamma-lactam based HDAC inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(4), 1218-1221.
101. Moradei, O.M.; Mallais, T.C.; Frechette, S.; Paquin, I.; Tessier, P.E.; Leit, S.M.; Fournel, M.; Bonfils, C.; Trachy-Bourget, M.C.; Liu, J.; Yan, T.P.; Lu, A.H.; Rahil, J.; Wang, J.; Lefebvre, S.; Li, Z.; Vaisburg, A.F.; Besterman, J.M., Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J. Med. Chem., 2007, 50(23), 5543-5546.
102. Suzuki, T.; Kouketsu, A.; Itoh, Y.; Hisakawa, S.; Maeda, S.; Yoshida, M.; Nakagawa, H.; Miyata, N. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. J. Med. Chem., 2006, 49(16), 4809-4812.
103. Wahhab, A.; Smil, D.; Ajamian, A.; Allan, M.; Chantigny, Y.; Therrien, E.; Nguyen, N.; Manku, S.; Leit, S.; Rahil, J.; Petschner, A.J.; Lu, A.H.; Nicolescu, A.; Lefebvre, S.; Montcalm, S.; Fournel, M.; Yan, T.P.; Li, Z.; Besterman, J.M.; Deziel, R. Sulfamides as novel histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(2), 336-340.
104. Dehmel, F.; Weinbrenner, S.; Julius, H.; Ciossek, T.; Maier, T.; Stengel, T.; Fettis, K.; Burkhardt, C.; Wieland, H.; Beckers, T. Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles. J. Med. Chem. 2008, 51(13), 3985-4001.
105. Pescatore, G.; Kinzel, O.; Attenni, B.; Cecchetti, O.; Fiore, F.; Fonsi, M.; Rowley, M.; Schultz-Fademrecht, C.; Serafini, S.; Steinkuhler, C.; Jones, P., Optimization of a series of potent and selective ketone histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(20), 5528-5532.
106. Hu, E.; Dul, E.; Sung, C.M.; Chen, Z.; Kirkpatrick, R.; Zhang, G.F.; Johanson, K.; Liu, R.; Lago, A.; Hofmann, G.; Macarron, R.; de los Frailes, M.; Perez, P.; Krawiec, J.; Winkler, J.; Jaye, M. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther., 2003, 307(2), 720-728.
107. Beckers, T.; Burkhardt, C.; Wieland, H.; Gimmnich, P.; Ciossek, T.; Maier, T.; Sanders, K. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int. J. Cancer., 2007, 121(5), 1138-1148.
108. Khan, N.; Jeffers, M.; Kumar, S.; Hackett, C.; Boldog, F.; Khramtsov, N.; Qian, X.; Mills, E.; Berghs, S.C.; Carey, N.; Finn, P.W.; Collins, L.S.; Tumber, A.; Ritchie, J.W.; Jensen, P.B.; Lichenstein, H.S.; Sehested, M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J., 2008, 409(2), 581-589.
109. Heidebrecht, R.W. Jr.; Chenard, M.; Close, J.; Dahlberg, W.K.; Fleming, J.; Grimm, J.B.; Hamill, J.E.; Harsch, A.; Haines, B.B.; Hughes, B.; Kral, A.M.; Middleton, R.E.; Mushti, C.; Ozerova, N.; Szewczak, A.A.; Wang, H.; Wilson, K.; Witter, D.J.; Secrist, J.P.; Miller, T.A. Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2). Bioorg. Med. Chem. Lett., 2009, 19(7), 2053-2058.
110. Fairlie, D.P.; Whitehouse, M.W.; Taylor, R.M. Zinc monoglycerolate--a slow-release source of therapeutic zinc: solubilization by endogenous ligands. Agents Actions, 1992, 36(1-2), 152-158.
111. Cantley, M.D.; Bartold, P.M.; Fairlie, D.P.; Rainsford, K.D.; Haynes, D.R. Histone deacetylase inhibitors as suppressors of bonedestruction in inflammatory diseases. J. Pharm. Pharmacol., 2012, 64(6),763-774.
112. Manku, S.; Allan, M.; Nguyen, N.; Ajamian, A.; Rodrigue, J.; Therrien, E.; Wang, J.; Guo, T.; Rahil, J.; Petschner, A.J.; Nicolescu, A.; Lefebvre, S.; Li, Z.; Fournel, M.; Besterman, J.M.; Deziel, R.; Wahhab, A. Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors. Bioorg. Med. Chem. Lett.; 2009, 19(7), 1866-1870.
113. Dehmel, F.; Ciossek, T.; Maier, T.; Weinbrenner, S.; Schmidt, B.; Zoche, M.; Beckers, T. Trithiocarbonates: exploration of a new head group for HDAC inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(17), 4746-4752.
114. Muraglia, E.; Altamura, S.; Branca, D.; Cecchetti, O.; Ferrigno, F.; Orsale, M.V.; Palumbi, M.C.; Rowley, M.; Scarpelli, R.; Steinkuhler, C.; Jones, P. 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(23), 6083-6087.
115. Whitehead, L.; Dobler, M.R.; Radetich, B.; Zhu, Y.; Atadja, P.W.; Claiborne, T.; Grob, J.E.; McRiner, A.; Pancost, M.R.; Patnaik, A.; Shao, W.; Shultz, M.; Tichkule, R.; Tommasi, R.A.; Vash, B.; Wang, P.; Stams, T. Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors. Bioorg. Med. Chem., 2011.
116. Bressi, J.C.; Jennings, A.J.; Skene, R.; Wu, Y.; Melkus, R.; De Jong, R.; O'Connell, S.; Grimshaw, C.E.; Navre, M.; Gangloff, A.R., Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg. Med. Chem. Lett., 2010, 20(10), 3142-3145.
117. Watson, P.J.; Fairall, L.; Santos, G.M.; Schwabe, J.W. Structure of HDAC3 bound to co-repressor and inositol tetraphosphate. Nature, 2012, 481(7381), 335-340.
118. Somoza, J.R.; Skene, R.J.; Katz, B.A.; Mol, C.; Ho, J.D.; Jennings, A.J.; Luong, C.; Arvai, A.; Buggy, J.J.; Chi, E.; Tang, J.; Sang, B.C.; Verner, E.; Wynands, R.; Leahy, E.M.; Dougan, D.R.; Snell, G.; Navre, M.; Knuth, M.W.; Swanson, R.V.; McRee, D.E.; Tari, L.W. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure, 2004, 12(7), 1325-1334.
119. Bottomley, M.J.; Lo Surdo, P.; Di Giovine, P.; Cirillo, A.; Scarpelli, R.; Ferrigno, F.; Jones, P.; Neddermann, P.; De Francesco, R.; Steinkuhler, C.; Gallinari, P.; Carfi, A., Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J. Biol. Chem., 2008, 283(39), 26694-26704.
120. Schuetz, A.; Min, J.; Allali-Hassani, A.; Schapira, M.; Shuen, M.; Loppnau, P.; Mazitschek, R.; Kwiatkowski, N.P.; Lewis, T.A.; Maglathin, R.L.; McLean, T.H.; Bochkarev, A.; Plotnikov, A.N.; Vedadi, M.; Arrowsmith, C.H. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J. Biol. Chem., 2008, 283(17), 11355-11363.
121. Scarpelli, R.; Di Marco, A.; Ferrigno, F.; Laufer, R.; Marcucci, I.; Muraglia, E.; Ontoria, J.M.; Rowley, M.; Serafini, S.; Steinkuhler, C.; Jones, P. Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(23), 6078-6082.
122. Wang, H.; Yu, N.; Song, H.; Chen, D.; Zou, Y.; Deng, W.; Lye, P.L.; Chang, J.; Ng, M.; Sun, E.T.; Sangthongpitag, K.; Wang, X.; Wu, X.; Khng, H.H.; Fang, L.; Goh, S.K.; Ong, W.C.; Bonday, Z.; Stunkel, W.; Poulsen, A.; Entzeroth, M. N-Hydroxy-1, 2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity. Bioorg. Med. Chem. Lett., 2009, 19(5), 1403-1408.
123. Heltweg, B.; Dequiedt, F.; Marshall, B.L.; Brauch, C.; Yoshida, M.; Nishino, N.; Verdin, E.; Jung, M., Subtype selective substrates for histone deacetylases. J. Med. Chem., 2004, 47(21), 5235-5243.
124. Kolle, D.; Brosch, G.; Lechner, T.; Lusser, A.; Loidl, P. Biochemical methods for analysis of histone deacetylases. Methods, 1998, 15(4), 323-331.
125. Hoffmann, K.; Brosch, G.; Loidl, P.; Jung, M. A non-isotopic assay for histone deacetylase activity. Nucleic Acids Res., 1999, 27(9), 2057-2058.
126. Wegener, D.; Wirsching, F.; Riester, D.; Schwienhorst, A. A fluorogenic histone deacetylase assay well suited for highthroughput activity screening. Chem. Biol., 2003, 10(1), 61-68.
127. Riester, D.; Hildmann, C.; Grunewald, S.; Beckers, T.; Schwienhorst, A. Factors affecting the substrate specificity of histone deacetylases. Biochem. Biophys. Res. Commun., 2007, 357(2), 439-445.
128. Gupta, P. PhD dissertation. 2012, University of Queensland.
129. Bradner, J.E.; West, N.; Grachan, M.L.; Greenberg, E.F.; Haggarty, S.J.; Warnow, T.; Mazitschek, R. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol., 2010, 6(3), 238-243.
130. Bieliauskas, A.V.; Pflum, M.K. Isoform-selective histone deacetylase inhibitors. Chem. Soc. Rev., 2008, 37(7), 1402-1413.
131. Perez-Balado, C.; Nebbioso, A.; Rodriguez-Grana, P.; Minichiello, A.; Miceli, M.; Altucci, L.; de Lera, A.R. Bispyridinium dienes: histone deacetylase inhibitors with selective activities. J. Med. Chem., 2007, 50(10), 2497-2505.
132. Kemp, M.M.; Wang, Q.; Fuller, J.H.; West, N.; Martinez, N.M.; Morse, E.M.; Weiwer, M.; Schreiber, S.L.; Bradner, J.E.; Koehler, A.N., A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold. Bioorg. Med. Chem. Lett., 2011, 21(14), 4164-4169.
133. Su, H.; Yu, L.; Nebbioso, A.; Carafa, V.; Chen, Y.; Altucci, L.; You, Q. Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group. Bioorg. Med. Chem. Lett., 2009, 19(22), 6284-6288.
134. Methot, J.L.; Chakravarty, P.K.; Chenard, M.; Close, J.; Cruz, J.C.; Dahlberg, W.K.; Fleming, J.; Hamblett, C.L.; Hamill, J.E.; Harrington, P.; Harsch, A.; Heidebrecht, R.; Hughes, B.; Jung, J.; Kenific, C.M.; Kral, A.M.; Meinke, P.T.; Middleton, R.E.; Ozerova, N.; Sloman, D.L.; Stanton, M.G.; Szewczak, A.A.; Tyagarajan, S.; Witter, D.J.; Secrist, J.P.; Miller, T.A., Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg. Med. Chem. Lett., 2008, 18(3), 973-978.
135. Hamblett, C.L.; Methot, J.L.; Mampreian, D.M.; Sloman, D.L.; Stanton, M.G.; Kral, A.M.; Fleming, J.C.; Cruz, J.C.; Chenard, M.; Ozerova, N.; Hitz, A.M.; Wang, H.; Deshmukh, S.V.; Nazef, N.; Harsch, A.; Hughes, B.; Dahlberg, W.K.; Szewczak, A.A.; Middleton, R.E.; Mosley, R.T.; Secrist, J.P.; Miller, T.A. The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(19), 5300-5309.